ImmunityBio

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atara Biotherapeutics

In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.

3 Stocks to Buy That Could Be the Next Biotech Breakthrough

Altimmune

Ardelyx

Cidara Therapeutics

FaZe Holdings Inc

Inovio Pharmaceuticals

Olaplex Holdings

RLX Technology

Silvergate Capital Corp

Tupperware

10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy Now? 10 To Watch Under $5

ImmunityBio, Inc. has a PDUFA date of May 23, 2023, for potential FDA approval of N-803 + BCG for the treatment of patients with BCG-unresponsive CIS non-muscle invasive bladder cancer. It is said that the global bladder cancer market could reach $11.5 billion by 2032.

ImmunityBio: FDA Approval Potential In May Of 2023

Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?

7 Top Penny Stocks Under $5; Time To Buy Now?

ImmunityBio, Inc. has a May 23 PDUFA for Anktiva with superb data in NMIBC. A recent small $50mn raise broke the stock's back.

ImmunityBio: Huge Slump On Small Raise Before Approval Raises Questions

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced Dr. Karim Chamie, Associate Professor of Urology at UCLA, will be presenting “Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG” at the ASCO Genitourinary Cancers Symposium (ASCO GU) conference in San Francisco, February 16-18.

ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG' at ASCO GU

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors

CULVER CITY, Calif.--( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results in its fully-enrolled metastatic pancreatic cancer study in third-line or greater subjects (QUILT 88) showing that the overall survival rate for patients continues to be double compared to historical survival rates after two or more prior lines of therapy. The results were presented at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) conference in San Francisco January 19-21.

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

ImmunityBio, Inc. presented strong data from its lead asset in multiple indications. Lead indication has a May 23 PDUFA.

ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances

CULVER CITY, Calif.--( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor

CULVER CITY, Calif.--( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022.

ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference

LOS ANGELES--( BUSINESS WIRE )--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.

LadRx Corporation Issues Corporate Update for 3Q22

ImmunityBio operates an effective development program for infectious disease, and more interestingly, oncology therapies. Its duly accepted BLA will be in the spotlight as its PDUFA date rolls around.

ImmunityBio: PDUFA Pending

FibroGen

Heron Therapeutics

Nkarta, Inc.

Relay Therapeutics, Inc.

Avidity Biosciences

Sana Biotechnology

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

7 Unknown Biotech Stocks That Could Rocket in 2023

Shares of ImmunityBio have lost nearly 90% of their value since merger with NantKwest last year. Ties to biotech billionaire Patrick Soon-Shiong are a net positive, especially in light of his success selling prior company Abraxis to Pfizer for $2.9 billion.

ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain

CULVER CITY, Calif.--(BUSINESS WIRE)--The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease. ImmunityBio, a leading clinical-stage immunotherapy company, filed the BLA based on positive results from a series of studies of the investigational treatment, including th

ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ

Amgen

Bristol-Myers

Gilead Sciences

Eli Lilly

Pfizer

Viatris

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

7 Best Pharmaceutical Stocks to Buy Now

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading clinical-stage immunotherapy company, today announced new positive data from the company's pivotal Phase 2/3 trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (QUILT 3032) and Phase 2 trial in advanced pancreatic cancer (QUILT 88). The results, which were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrate the strong and diverse g

ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

ImmunityBio has finally submitted the Anktiva (N-803) and BCG combination BLA in NMIBC ahead of the final clinical results presentation at ASCO. The company is still moving forward with multiple cancer and infectious disease programs with Anktiva. An FDA approval would improve the outlook for these programs.

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803, a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 disease. The BLA is supported by the results of Immunit

ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, in Chicago. QUILT 3.032 Oral Presentation: Principal Investigator Karim Chamie, M.D., Associate Professor of Urology at UCLA, will present final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and

ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for non-small cell lung cancer (NSCLC). The Lung Cancer Master Protocol trial (Lung-MAP) includes a study of Anktiva™ (N-803) plus Keytruda (pembrolizumab) versus investigator choice of standard-of-care chemotherapy in patients with non-small cell lung cancer (NS

ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months of follow-up as of January 14, 2022. All data for QUILT-3.032, which is studying VesAnktiva™ plus BCG in subjects with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), have been locked and analyzed. The results continue t

ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

BLA filing of Anktiva + BCG in BCG-unresponsive cancer in Situ non-muscle invasive bladder cancer patients is expected Q1 of 2022.

ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced study results that further demonstrate the potential for use of memory-like cytokine-enriched natural killer (m-ceNK) cells for the treatment of cancer. ImmunityBio has successfully scaled the process of generating over 20 billion m-ceNK cells from a single extraction of white blood cells from a donor or patient, and reports promising clinical data supporting the ongoi

Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio's Scaled m-ceNK Clinical Program

News for ImmunityBio Stock (IBRX)